Minn, Ann Kaiser Radiation Oncology Department

Rigel Pharmaceuticals is a biotechnology company based in South San Francisco, CA, dedicated to the discovery, development, and provision of innovative therapies that significantly enhance the lives of patients with hematologic disorders and cancer. The company's pipeline includes proprietary programs such as IRAK1 and RIPK1, as well as partnered programs with leading pharmaceutical companies like BerGenBio, Daiichi-Sankyo, Grifols, Kissei Knight, Lilly, Medison, and Novo Nordisk. Rigel Pharmaceuticals is committed to developing novel treatments, including TAVALISSE for thrombocytopenia in adult patients with chronic immune thrombocytopenia and REZLIDHIA for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.Generated from the website

Denali Therapeutics is a biotechnology company based in South San Francisco, CA, dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development. With a focus on Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative diseases, Denali utilizes groundbreaking scientific insights and deep expertise in genetics and pathology to develop effective molecular therapeutics. Driven by a commitment to partnering with patients, Denali's core portfolio consists of programs at various stages of clinical and preclinical development, aiming to directly address the causes and risk factors of neurodegenerative diseases. With a team of passionate scientists and drug developers, Denali believes in the power of collaboration and is continuously seeking new assets, technologies, and scientific insights to advance their mission of defeating degeneration.Generated from the website